Loading stock data…
GSK
$51.61-0.70 (-1.34%)
Market ClosedLast close May 1
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GSK plc in the Healthcare sector is trading at $51.61. The stock is currently 16% below its 52-week high of $61.70, remaining 8.6% above its 200-day moving average. Technical signals show oversold RSI of 21 and bearish MACD signal, explaining why GSK maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 21) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$51.61
Potential Upside
49.5%
Whystock Fair Value$77.17
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Hold
Mean target$57.65+11.7%
Range$47.00 – $70.00
Fundamentals
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It oper...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$111.97B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
14.83
Beta
Defensive asset. Lower volatility than the S&P 500.
0.35
Div Yield
Strong income play. Yield provides a meaningful total return floor.
319.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
20.90%
Volume
Today's trading volume
3.94M
Recent News
GSK (GSK) Completes $950M Acquisition to Expand Drug Pipeline
GSK plc (NYSE:GSK) ranks among the best low-risk investments in May 2026. GSK plc (NYSE:GSK) stated on April 15 that it had completed the acquisition of 35Pharma Inc., a private clinical-stage biopharmaceutical firm based in Canada. The $950 million purchase gives GSK plc (NYSE:GSK) complete control of 35Pharma and its pipeline, which includes HS235, a […]
GSK Juggles Alzheimer’s Setback And Leadership Shift With Product Progress
GSK (LSE:GSK) and Alector have discontinued their phase 2 trial of an Alzheimer's drug candidate after the study did not meet efficacy goals. The decision effectively ends a high profile collaboration in neurodegenerative research between the two companies. Separately, GSK received UK approval for Lynavoy (linerixibat) to treat primary biliary cholangitis. The company has also appointed Roanne Parry as Chief People Officer, a move that may shape its global people and culture agenda. GSK,...
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could shape the outlook.
IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View
Ionis tops Q1 estimates and lifts 2026 outlook, drives shares higher as strong drug sales and milestone revenues fuel growth.
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.